[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100636578":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":27,"centralContacts":36,"locations":42,"responsibleParty":60,"collaborators":64,"id":67,"slug":68,"hasResults":69,"nctId":70,"briefTitle":71,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":69,"sex":74,"minAge":75,"maxAge":27,"enrollmentInfo":76,"targetDuration":27,"studyType":79,"phases":80,"briefSummary":82,"conditions":83,"keywords":86,"overallStatus":91,"whyStopped":27,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},{"fullName":5,"class":6},"Samsung Medical Center","OTHER",[8,16],{"label":9,"type":10,"description":11,"interventionNames":12},"Early screening group","EXPERIMENTAL","AI-ECG and\u002For CT ECV analysis with standard atrial fibrillation treatment",[13,14,15],"Diagnostic Test: AI-ECG analysis","Diagnostic Test: CT-ECV analysis","Other: Atrial fibrillation treatment",{"label":17,"type":18,"description":19,"interventionNames":20},"Usual care group","ACTIVE_COMPARATOR","Standard atrial fibrillation treatment",[15],[22,28,32],{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":27},"DIAGNOSTIC_TEST","AI-ECG analysis","Artificial Intelligence-enhanced Electrocardiogram (AI-ECG), developed by Mayo Clinic, is gaining attention as a non-invasive screening tool. AI-ECG predicts myocardial amyloid deposition based on a standard 12-lead ECG with high accuracy, AUC 0.84(95% CI 0.82-0.86) In particular, it demonstrated superior performance with an AUC of 0.9 or higher in ECGs exhibiting low voltage or pseudo-infarction patterns, suggesting its potential to detect the disease even before structural changes become apparent.",[9],null,{"type":23,"name":29,"description":30,"armGroupLabels":31,"otherNames":27},"CT-ECV analysis","Myocardial Extracellular Volume (CT-ECV) analysis using cardiac CT is a tissue characterization technique that can be easily added to conventional cardiac CT protocols, enabling the quantification of myocardial fibrosis or infiltrative diseases. Among 874 subjects who underwent coronary CT, 12.4% exhibited a CT-ECV of ≥ 35%, and cardiac amyloidosis was incidentally discovered in 14.3% of these individuals.",[9],{"type":6,"name":33,"description":34,"armGroupLabels":35,"otherNames":27},"Atrial fibrillation treatment","Standard care and treatment in accordance with established AF guidelines.",[9,17],[37],{"name":38,"role":39,"phone":40,"phoneExt":27,"email":41},"Ju Youn Kim, Ph.D","CONTACT","82+ 10-5482-7307","kzzoo921@gmail.com",[43],{"facility":5,"status":27,"city":44,"state":44,"zip":45,"country":46,"countryCode":27,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"Seoul","06351","South Korea",{"type":48,"coordinates":49},"Point",[50,51],126.9784,37.566,{"lat":51,"lon":50},[54,56],{"name":38,"role":39,"phone":55,"phoneExt":27,"email":41},"82+ 2-3410-3419",{"name":57,"role":39,"phone":58,"phoneExt":27,"email":59},"Ju hee Lee, RN","82+ 2-2148-7611","phacyde12@gmail.com",{"type":61,"investigatorFullName":62,"investigatorTitle":63,"investigatorAffiliation":5,"oldNameTitle":27,"oldOrganization":27},"PRINCIPAL_INVESTIGATOR","Ju Youn Kim","Professor",[65],{"name":66,"class":6},"Mayo Clinic","100636578","early-detection-of-concealed-cardiac-amyloidosis-using-ai-ecg-and-ct-derived-extracellular-volume-in-patients-with-atrial-fibrillation-100636578",false,"NCT07567508","Early Detection of Concealed Cardiac Amyloidosis Using AI-ECG and CT-Derived Extracellular Volume in Patients With Atrial Fibrillation","SEARCH-AF","Inclusion Criteria:\n\n* Adults aged 19 or older who have provided voluntary written informed consent.\n* Patients with a history of AF (paroxysmal or persistent) and one or more red-flag symptoms\u002Fsigns.\n* Patients who can undergo at least one of the following: AI-ECG analysis or CT-ECV analysis.\n\nExclusion Criteria:\n\n* Patients previously diagnosed with cardiac amyloidosis (AL or ATTR).\n* Patients with severe heart failure (NYHA class IV) or terminal illness with a life expectancy of less than 1 year.\n* Patients deemed inappropriate for participation by the investigator.","ALL","19 Years",{"count":77,"type":78},500,"ESTIMATED","INTERVENTIONAL",[81],"NA","This study investigates the clinical efficacy of a non-invasive screening protocol using AI-ECG and CT-ECV analysis for cardiac amyloidosis. The study targets on atrial fibrillation(AF) patients with \"red-flag\" indicators.\n\nParticipants are randomized 1:1 into either an early screening or usual care group.\n\n* Early screening group : AI- ECG and\u002For CT-ECV analysis + AF treatment\n* Usual care group : AF treatment Both groups followed for 2 years to compare CA detection rates and clinical outcomes.",[84,85],"Atrial Fibrillation (AF)","Cardiac Amyloidosis",[87,88,89,90],"AI-ECG","Amyloidosis","Cardiac amyloidosis","Atrial Fibrillation","NOT_YET_RECRUITING","2026-04-28",{"date":94,"type":95},"2026-05-05","ACTUAL",{"date":97,"type":78},"2026-05",{"date":99,"type":78},"2029-12-31",{"name":5,"class":6},1]